Type 2 Diabetes Archive
Investigators examined the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes.
Cirrhosis is associated with an increased risk for diabetes mellitus among patients living with HIV.
Glycemic control with once-weekly dulaglutide was similar to that with insulin glargine in patients with type 2 diabetes and moderate to severe chronic kidney disease.
Investigators examined the association between risk for T2D and comorbid depressive and anxiety symptoms.
Investigators examined gender differences in baseline characteristics and outcomes in patients with t2d and ASCVD.
Glargine 300 is associated with significantly lower annualized rates of documented symptomatic hypoglycemia than Gla-100.
Antidiabetic agents for the treatment of diabetes including maintenance and max doses.
Investigators assessed whether intensification of type 2 diabetes therapy affects health status and quality of life.
The role of low-dose levothyroxine to increase β-oxidation of fatty acids and decreases intrahepatic lipids in patients with type 2 diabetes was examined.
IDegLira is a cost-effective alternative to basal bolus insulin therapy with insulin glargine U100 plus insulin aspart.
Study shows increased risks of autism spectrum disorder in association with types 1, 2, gestational diabetes.
CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy
Investigators evaluated the performance of the CAPPRI in assessing health-related quality-of-life outcomes in patients with diabetic distal sensorimotor polyneuropathy.
Metformin use in patients with chronic kidney disease and the risk for lactic acidosis was examined.
Investigators compared 2 methods of delivering bolus insulin, pen vs patch, using metrics from continuous glucose monitoring.
Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.
Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.
Investigators analyzed real world data to examine the risk for below-knee amputations in patients with type 2 diabetes taking canagliflozin vs other medications.
The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.
The safety and efficacy of exenatide alone or in combination with basal insulin in surgery and medicine patients with type 2 diabetes examined.
MEDI0382 reduced body weight and normalized fasting and postprandial blood glucose levels in patients with type 2 diabetes.
Investigators examined the efficacy of liraglutide for the prevention of dementia in elderly patients with type 2 diabetes.
Semaglutide was associated with HbA1c and body weight reductions compared with patients taking dulaglutide.
The effect of high-intensity statins compared with low-intensity statins on glycemic control was examined.
Investigators examined the effect of exenatide on estimated glomerular filtration rate, new macroalbuminuria, and 2 renal composites.
Investigators examined renal outcomes when controlling cardiovascular risk factors, such as blood pressure, LDL-C, and HbA1c.
Investigators examined the prevalence of chronic kidney disease in adults with type 1 diabetes compared with type 2 diabetes.
Single blood sample looking at fasting glucose and HbA1c was a key predictor of subsequent diagnosis of diabetes.
In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.
Investigators used the Information-Motivation-Behavioral skills model of adherence to examine associations between patient characteristics and barriers to adherence to treatment for type 2 diabetes.
A retrospective cohort study was conducted to determine whether individuals with preexisting type 2 diabetes are at increased risk of developing Parkinson disease.
Outcomes associated with metformin use for diabetes in patients requiring kidney transplantation were assessed in an observational study linking Scientific Registry of Transplant Recipient data with US pharmacy claims data.
Investigators examined the safety and efficacy of empagliflozin 10mg and linagliptin 5 mg in patients uncontrolled on linagliptin.
In most patients with type 2 diabetes, the target should be an HbA1c level between 7 and 8 percent.
Impaired global longitudinal strain and left ventricular hypertrophy may be predictive of incident heart failure in patients with asymptomatic type 2 diabetes.
The correlation between the fraction of outpatient diabetes medications reconciled over a six-month period and the composite primary outcome over the subsequent six months was assessed.
Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.
To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.
Results demonstrated an incidence rate of 391/100,000 person years was calculated based on the 163 patients who were hospitalized with lactic acidosis during the follow-up period.
This study demonstrated the importance of early screening and diagnosis of type 2 diabetes in mothers and their offspring.
Investigators examined the time to first event composing of cardiovascular death, myocardial infarction, or stroke.
A study sought to determine the relationship between glycemic status and cognition in people living with HIV.
Investigators examined predictors of success of switching from insulin to liraglutide in patients with type 2 diabetes.
Investigators sought to determine the safety and efficacy of MK-1293 insulin glargine and Lantus in type 2 diabetes.
Greater awareness of clinical and cost implications of gaps for patients with lower-severity gestational diabetes may improve postdelivery testing and referral.
Researchers assessed whether semaglutide-induced weight loss was related to gastrointestinal adverse events.
Investigators sought to determine baseline and clinical characteristics associated with response to insulin glargine in patients with type 2 diabetes.
Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.
Oral semaglutide 14 mg led to statistically significant improvement in hemoglobin A1c levels and weight loss in adults with type 2 diabetes.
Fewer Major Adverse Cardiovascular Events With New Antihyperglycemic Drugs With Lower Hypoglycemic Risk
Investigators proposed that reduction in MACE may be proportional to the magnitude of HbA1c reduction seen with newer antihyperglycemic agents.
Researchers conducted a systemic review and met-analysis to examine the effect of type 2 diabetes on heart rate variability.
These findings can inform clinical practice in that type 2 diabetes should be considered in ADHD even in the absence of other known risk factors.
Investigators sought to determine whether targeting systolic blood pressure of 140 mmHg in patients with type 2 diabetes would result in adverse CV outcomes.
Researchers performed a cohort study involving 903 adults who were known to be free of diabetes or prediabetes during a visit conducted in 1997 to 1999.
Insulin Pen Devices comparison chart for patients with diabetes mellitus.
Perioperative major adverse cardiovascular and cerebrovascular events may be more common in patients with diabetes.
Investigators sought to determine an association between diabetes and HbA1C with postoperative outcomes.
Investigators examined changes in weight from childhood to early adulthood and the risk for developing type 2 diabetes.
Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after 6 months of treatment.
Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.
There is a lack of transparency throughout the insulin supply chain. It is unclear precisely how the dollars flow and how much each intermediary profits.
Treatment strategies targeting hypertension, hyperlipidemia, and hyperglycemia may improve outcomes in patients with type 2 diabetes.
Further research is needed on whether high 25(OH)D might prevent type 2 diabetes or transition of prediabetes to diabetes.
To date, published experience with continuous subcutaneous insulin infusion use in the hospital is limited to just a few institutions, and primarily to those instances involving transitioning of the therapy from the outpatient to inpatient setting.
A community health worker-led diabetes self-management education program is associated with sustained improvement in hemoglobin A1c.
Studies on the antifracture effectiveness of antiosteoporosis medications (or nonpharmacologic treatments) should account for death as a competing risk.
Patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation rates and less hypoglycemia compared with patients starting NPH insulin.
Maintaining a basal insulin regimen over 12 or 24 months in a patient who has not yet reached the HbA1c <7% target provides little additional benefit toward reaching this goal.
Researchers found that the risk of developing type 2 diabetes was increased for lesbian and bisexual women vs heterosexual women.
Type 2 diabetes is independently associated with a greater risk of renal cell carcinoma in women, but not in men.
In European T2D cases, the researchers identified a novel signal near GABRR1, which was associated with microalbuminuria.
Markers of reproductive history, including age of menarche and parity, may be tied to future diabetes risk in women with a body mass index ≥25.
Upon review of the proposed supplemental New Drug Application (sNDA), the FDA has determined that the communication plan is no longer needed as an element of the REMS to ensure the benefits of Afrezza outweigh its risks.
The paradoxical finding of accelerated wound healing and increase in HbA1c in participants with better baseline glycemic control requires confirmation in further studies.
Insulin products chart with pharmacokinetic properties.
Researchers showed that improved glycemic control is associated with higher bone resorption, possibly reflecting normalization rather than an abnormal increase in bone resorption.
The authors advised clinicians to carefully consider which antipsychotics they prescribe their patients with metabolic dysfunction, as some are known to be diabetogenic.
Menstrual dysfunction is common in girls with recently diagnosed type 2 diabetes, and does not improve with 2years of anti-hyperglycemic treatment.
Study compared the real-world effectiveness of canagliflozin 300 mg vs dapagliflozin 10 mg on HbA1c reduction in patients with type 2 diabetes.
Researchers used multiparametric cardiovascular magnetic resonance imaging to examine the correlation between aortic stiffness and LV geometry in younger adults with type 2 diabetes.
Knowing that certain characteristics increase the risk for dermatology patients who may have metabolic syndrome will enable clinicians to identify patients who may have specific cardiovascular risks.
The CDC conducted a study to estimate the prevalence of diagnosed diabetes among adults in 2016 by primary type.
Researchers found that estimation of hip fracture risk without accounting for death as a competing event results in an overestimation of fracture risk.
Results suggest that circadian preference and meal timing are novel and possibly modifiable risk factors for obesity in type 2 diabetes.
Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.
Further clinical trials are needed to explore the potential beneficial effect of vitamin D supplementation, via fortified foods and/or dietary supplements, on insulin resistance, and possibly on weight management.
Ethnicity,race, markers of insulin resistance, and genetic factors might help identify obese youth at risk for developing fatty liver.
HbA1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes and appears to be more powerful than average HbA1c in predicting all-cause death.
Researchers examined the choroidal layer thickness in eyes of patients with diabetes to compare the findings based on medical history of systemic diabetes treatments and stage of diabetic retinopathy.
One-hour plasma glucose is a useful predictor of retinopathy risk, has a predictive value similar to that of 2-hour plasma glucose, and may be considered as an alternative glucose time point during an oral glucose tolerance test.
Family and friends' autonomy support may lead to better glycemic control by reducing distress among patients with diabetes.
SGLT-2 inhibitors and GLP-1 agonists associated with better mortality outcomes than DPP-4 inhibitors for type 2 diabetes
SGLT-2 inhibitors or GLP-1 agonists were associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.
For overweight or obese adults with T2D, a long-term weight loss intervention is associated with a reduction in long-term disability.
In patients with insulin-treated diabetes and sepsis, increased highest glucose levels and glycemic variability have a significant illness severity-adjusted association with decreasing in-hospital mortality.
Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.
In obese subjects with and without type 2 diabetes, oxyntomodulin significantly augments glucose-dependent insulin secretion.
Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline.
Future research should further investigate the process and influences on clinician decision-making regarding individualizing glucose targets for high-risk geriatric patients, including the influence of training and practice environment.
Compared to men who were never overweight, those overweight at age 7 who returned to a normal body mass index by age 13 had no increased risk for developing type 2 diabetes.
The type of sciatic nerve lesions observed in patients with diabetic peripheral neuropathy was found to differ in type 1 and type 2 diabetes.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow